Molecular Medicine

, Volume 23, Issue 1, pp 204–214 | Cite as

Tolerogenic Dendritic Cells Induced by BD750 Ameliorate Proinflammatory T cell Responses and Experimental Autoimmune Encephalitis in Mice

  • Yan Zhou
  • Xiao Leng
  • Hua Li
  • Shuxia Yang
  • Tai Yang
  • Limei Li
  • Ying Xiong
  • Qiang Zou
  • Yang Liu
  • Yantang Wang
Research Article


BD750, a novel JAK3/STAT5 inhibitor, can inhibit T cell proliferation. This study aims to evaluate whether BD750 can induce tolerogenic dendritic cells (tolDC) and their function in experimental autoimmune encephalitis (EAE) in mice. Following BD750 treatment, lipopolysaccharide (LPS)-induced maturation of DCs, allogeneic T cell proliferation, Th1 and Th17 cell functional differentiation, and STAT5 and AKT activation were determined. The effect of tolDC loaded with antigen peptide on the development and severity of EAE and splenic Th1 and Th17 cell responses was determined. In comparison with LPS-induced mature DCs (mDCs), BD750 treatment induced tolDC with lower expression levels of costimulatory molecules and proinflammatory cytokines and lower levels of STAT5 phosphorylation. TolDC inhibited allogeneic T cell proliferation and reduced Th1 and Th17 responses. Adoptive transfer of tolDC loaded with myelin oligodendrocyte glycoprotein35-55 inhibited the development and severity of EAE in mice, accompanied by reduced numbers of inflammatory infiltrates and decreased levels of demyelination in the spinal cord tissues. In addition, treatment with tolDC loaded with antigen peptide also significantly reduced the frequency of splenic Th1 and Th17 cells in EAE mice. The effects of tolDC were similar to that of JAK/STAT inhibitor CP690550-treated DCs. In conclusion, treatment with BD750 induced tolDC that inhibited proinflammatory T cell immunity in vitro and in vivo. BD750 and tolDC may be valuable for development of new therapies for EAE and other autoimmune diseases.



We thank Medjaden Bioscience Limited for assisting in the preparation of this manuscript. This work was supported by grants from the National Natural Science Foundation of China (nos. 81202363, 81302786, 81273530), the Research Fund of Development and Regeneration Key Laboratory of Sichuan Province (no. SYS16-002), the Program for Provincial Universities Innovative Research Team in Sichuan Province (no. 13TD0028), the Innovative Research Team Fund of Chengdu Medical College (no. CYTD15-01), the Scientific Research Fund of Sichuan Provincial Education Department (no. 16ZB0271) and the National Undergraduates Innovating Experimentation Project (no. 201513705005).


  1. 1.
    Pelletier D, Hafler DA. (2012) Fingolimod for multiple sclerosis. New Engl. J. Med. 366:339–47.CrossRefGoogle Scholar
  2. 2.
    Compston A, Coles A. (2008) Multiple sclerosis. Lancet. 372:1502–17.CrossRefGoogle Scholar
  3. 3.
    Viglietta V, Baecher-Allan C, Weiner HL, Hafler DA. (2004) Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J. Exper. Med. 199:971–9.CrossRefGoogle Scholar
  4. 4.
    Gross CC, Jonuleit H, Wiendl H. (2012) Fulfilling the dream: tolerogenic dendritic cells to treat multiple sclerosis. Eur. J. Immunol. 42:569–72.CrossRefGoogle Scholar
  5. 5.
    Steinman RM. (2012) Decisions about dendritic cells: past, present, and future. Annu. Rev. Immunol. 30:1–22.CrossRefGoogle Scholar
  6. 6.
    Steinman RM, Hawiger D, Nussenzweig MC. (2003) Tolerogenic dendritic cells. Annu. Rev. Immunol. 21:685–711.CrossRefGoogle Scholar
  7. 7.
    Torres-Aguilar H, Blank M, Jara LJ, Shoenfeld Y. (2010) Tolerogenic dendritic cells in autoimmune diseases: crucial players in induction and prevention of autoimmunity. Autoimmun. Rev. 10:8–17.CrossRefGoogle Scholar
  8. 8.
    Price S. (2010) Therapeutic effects of tolerogenic dendritic cells. Nat. Rev. Rheumatol. 6:674.CrossRefGoogle Scholar
  9. 9.
    Llanos C, Mackern-Oberti JP, Vega F, Jacobelli SH, Kalergis AM. (2013) Tolerogenic dendritic cells as a therapy for treating lupus. J. Clin. Immunol. 148:237–45.CrossRefGoogle Scholar
  10. 10.
    Stoop JN, et al. (2010) Therapeutic effect of tolerogenic dendritic cells in established collagen-induced arthritis is associated with a reduction in Th17 responses. Arthritis Rheum. 62:3656–65.CrossRefGoogle Scholar
  11. 11.
    Kang HK, Liu M, Datta SK. (2007) Low-dose peptide tolerance therapy of lupus generates plasmacytoid dendritic cells that cause expansion of autoantigen-specific regulatory T cells and contraction of inflammatory Th17 cells. J. Immunol. 178:7849–58.CrossRefGoogle Scholar
  12. 12.
    Farias AS, et al. (2013) Vitamin D3 induces IDO+ tolerogenic DCs and enhances Treg, reducing the severity of EAE. CNS Neurosci. Ther. 19:269–77.CrossRefGoogle Scholar
  13. 13.
    Raiotach-Regue D, et al. (2012) Stable antigen-specific T-cell hyporesponsiveness induced by tolerogenic dendritic cells from multiple sclerosis patients. Eur. J. Immunol. 42:771–82.CrossRefGoogle Scholar
  14. 14.
    Matsumoto T, et al. (2013) Protein kinase C inhibitor generates stable human tolerogenic dendritic cells. J. Immunol. 191:2247–57.CrossRefGoogle Scholar
  15. 15.
    Liu Y, et al. (2013) BD750, a benzothiazole derivative, inhibits T cell proliferation by affecting the JAK3/STAT5 signalling pathway. Brit. J. Pharmacol. 168:632–43.CrossRefGoogle Scholar
  16. 16.
    Rivas-Caicedo A, et al. (2009) Jak3 is involved in dendritic cell maturation and CCR7-dependent migration. PLoS One 4:e7066.CrossRefGoogle Scholar
  17. 17.
    Zhou Y, et al. (2016) Tolerogenic dendritic cells generated with tofacitinib ameliorate experimental autoimmune encephalomyelitis through modulation of Th17/Treg balance. J. Immunol. Res. 2016:5021537.PubMedPubMedCentralGoogle Scholar
  18. 18.
    Bell BD, et al. (2013) The transcription factor STAT5 is critical in dendritic cells for the development of TH2 but not TH1 responses. Nat. Immunol. 14:364–71.CrossRefGoogle Scholar
  19. 19.
    Stromnes IM, Goverman JM. (2006) Active induction of experimental allergic encephalomyelitis. Nat. Protoc. 1:1810–19.CrossRefGoogle Scholar
  20. 20.
    Inaba K, et al. (1992) Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J. Exper. Med. 176:1693–702.CrossRefGoogle Scholar
  21. 21.
    Yanagawa Y, Onoe K. (2002) CCL19 induces rapid dendritic extension of murine dendritic cells. Blood. 100:1948–56.CrossRefGoogle Scholar
  22. 22.
    Tanaka H, Demeure CE, Rubio M, Delespesse G, Sarfati M. (2000) Human monocyte-derived dendritic cells induce naive T cell differentiation into T helper cell type 2 (Th2) or Th1/Th2 effectors. Role of stimulator/responder ratio. J. Exper. Med. 192:405–12.CrossRefGoogle Scholar
  23. 23.
    Segura E, et al. (2013) Human inflammatory dendritic cells induce Th17 cell differentiation. Immunity. 38:336–48.CrossRefGoogle Scholar
  24. 24.
    Harry RA, Anderson AE, Isaacs JD, Hilkens CM. (2010) Generation and characterisation of therapeutic tolerogenic dendritic cells for rheumatoid arthritis. Ann. Rheum. Dis. 69:2042–50.CrossRefGoogle Scholar
  25. 25.
    Sonobe Y, et al. (2012) Midkine inhibits inducible regulatory T cell differentiation by suppressing the development of tolerogenic dendritic cells. J. Immunol. 188:2602–11.CrossRefGoogle Scholar
  26. 26.
    Mansilla MJ, et al. (2015) Beneficial effect of tolerogenic dendritic cells pulsed with MOG autoantigen in experimental autoimmune encephalomyelitis. CNS Neurosci. Therap. 21:222–30.CrossRefGoogle Scholar
  27. 27.
    van de Laar L, et al. (2011) Tight control of STAT5 activity determines human CD34-derived interstitial dendritic cell and langerhans cell development. J. Immunol. 186:7016–24.CrossRefGoogle Scholar
  28. 28.
    Toniolo PA, et al. (2015) Inhibiting STAT5 by the BET bromodomain inhibitor JQ1 disrupts human dendritic cell maturation. J. Immunol. 194:3180–90.CrossRefGoogle Scholar
  29. 29.
    Giannoukakis N, Phillips B, Finegold D, Harnaha J, Trucco M. (2011) Phase I (safety) study of autologous tolerogenic dendritic cells in type 1 diabetic patients. Diabetes Care. 34:2026–32.CrossRefGoogle Scholar

Copyright information

© The Author(s) 2017

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, and provide a link to the Creative Commons license. You do not have permission under this license to share adapted material derived from this article or parts of it.

The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

To view a copy of this license, visit (

Authors and Affiliations

  • Yan Zhou
    • 1
  • Xiao Leng
    • 2
  • Hua Li
    • 3
  • Shuxia Yang
    • 2
  • Tai Yang
    • 2
  • Limei Li
    • 2
  • Ying Xiong
    • 1
  • Qiang Zou
    • 2
  • Yang Liu
    • 2
  • Yantang Wang
    • 2
  1. 1.Department of Pediatrics and Department of Emergency, West China Second University HospitalSichuan UniversityChengdu, SichuanChina
  2. 2.Department of Immunology, School of Basic Medical SciencesChengdu Medical CollegeChengdu, SichuanChina
  3. 3.Cancer CenterChengdu Military General HospitalChengdu, SichuanChina

Personalised recommendations